The emergence and spread of drug-resistant bacteria is a significant global problem to public health. It is estimated that the number of deaths due to antimicrobial resistance (AMR) in 2050 could reach 10 million annually if appropriate countermeasures are not implemented. Against this backdrop, the AMR Action Fund was established in July 2020 to support the clinical development of new antimicrobial agents and to achieve a sustainable market for antimicrobial agents. The fund aims to commercialize two to four new antimicrobial agents by 2030 by providing a total of US$1.0 billion in investments and technical assistance to several small biotechnology companies. As of the end of May 2023, the fund has announced investments in a total of five companies: Adaptive Phage Therapeutics, Venatorx Pharmaceuticals, BioVersys AG, Vedanta Biosciences, and Pattern Bioscience. By contributing a total of US$20 million to this fund, Daiichi Sankyo is working to promote the development of innovative antimicrobial agents and thereby contribute to the early resolution of the global AMR problem.

AMR Action Fund website